Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul 2:4:51.
doi: 10.21037/tgh.2019.06.08. eCollection 2019.

PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma

Kai Wei Tan  1 , Ann-Marie Chacko  1 , Valerie Chew  2
Affiliations
Editorial

PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma

Kai Wei Tan et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematic diagram summarising the potential of PD-1high CD8+ TILs subpopulation as predictive biomarker towards anti-PD-1 ICI therapy. Patient samples were classified based on the presence of PD-1high CD8+ TILs subpopulation. The TME of patients with the subpopulation differ from those without the subpopulation both genetically and phenotypically and may potentially function as a predictive biomarker for PD-1-targeted therapy. PD-1, programmed cell death protein 1; TIL, tumour infiltrating lymphocyte; ICI, immune checkpoint inhibitor; TME, tumour microenvironment.
See this image and copyright information in PMC

Comment on

References

    1. Global Burden of Disease Cancer Collaboration , Fitzmaurice C, Akinyemiju TF, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2018;4:1553-68. 10.1001/jamaoncol.2018.2706 - DOI - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. 10.3748/wjg.v20.i15.4115 - DOI - PMC - PubMed
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. 10.1016/S0140-6736(17)31046-2 - DOI - PMC - PubMed
    1. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52. 10.1016/S1470-2045(18)30351-6 - DOI - PubMed